NIH Study Section Members Acknowledge Major Flaws In The Reviewing System

Three times a year, in conference rooms at the National Institutes of Health's Bethesda, Md., campus, about 1,440 permanent members of 100 study sections (accompanied by an annual total of about 1,800 ad hoc members) meet for two days to review 9,000 grant proposals. Critics of the system charge that it is cumbersome; needlessly hard on both reviewers and the reviewed; and rife with the potential for incompetent decisions, abuse of power, and conflicts of interest. Even its supporters acknowled

Written byRobert Finn
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

Fred Bookstein OPEN TO SUGGESTION: Fred Bookstein urges a new ranking system for grant proposals.

A study section meeting is the culmination of a process that begins eight weeks earlier, when each of its members is mailed boxes containing 75 to 100 grant applications. Each of the applications is 25 pages long, not counting supporting documents, which themselves can run to 50 pages or more per application.

Although each reviewer is expected to read every one of those applications, he or she is assigned to write detailed critiques of just seven to 12 of them. Each application will have two such reviewers--designated the primary and the secondary--as well as a "reader," a reviewer who must be prepared to discuss the application in detail, but who isn't required to write a critique.

At the meeting, once the primary, the secondary, and the reader have delivered their opinions of a particular application, there is ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies